R. Papotti

Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma

P. Gobbi, S. Sacchi, M. Federico, 2020, Hematological oncology.

Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.

S. Sacchi, S. Bettelli, A. Maiorana, 2021, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study

L. Larocca, S. Hohaus, L. Leoncini, 2022, Leukemia.

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

R. Foà, G. Fronza, A. Cuneo, 2023, Leukemia.

P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE

R. Foà, L. Ballotta, A. Cuneo, 2022, HemaSphere.

Clinico-Pathological, Cytogenetic and Molecular Profiles of Primary Cutaneous Diffuse Large B-Cell Lymphomas.

S. Sacchi, L. Braglia, S. Bettelli, 2023, Human pathology.

Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders

F. Pozzo, V. Gattei, C. Mazzaro, 2023, British journal of haematology.

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience

A. Cuneo, R. Marasca, R. Moia, 2024, HemaSphere.

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia

F. Pozzo, A. Tafuri, A. Chiarenza, 2024, Leukemia.